RESEARCH

Open Access

Cytotoxic effects of the compound *cis*-tetraammine (oxalato)ruthenium(III) dithionate on K-562 human chronic myelogenous leukemia cells

Flávia de Castro Pereira¹, Aliny Pereira de Lima¹, Cesar Augusto Sam Tiago Vilanova-Costa¹, Wanessa Carvalho Pires¹, Alessandra de Santana Braga Barbosa Ribeiro¹, Lucas Carlos Gomes Pereira¹, Luiz Alfredo Pavanin², Wagner Batista dos Santos³ and Elisângela de Paula Silveira-Lacerda^{1*}

Abstract

Chemotherapy is a common treatment for leukemia. Ruthenium complexes have shown potential utility in chemotherapy and photodynamic therapy. The identification of new chemotherapeutics agents is critical for further progress in the treatment of leukemia. Ruthenium complexes generally have lower toxicities compared to cisplatin attributed to their specific accumulation in cancer tissues. Based on these evidences, in the present work we studied the cytotoxic activity of the ruthenium(III) compound *cis*-tetraammine(oxalato)ruthenium(III) dithionate - {*cis*-[Ru(C₂O₄) (NH₃)₄]₂(S₂O₆)} against human chronic myelogenous leukemia cells (K-562) tumor cell line. The tested compound induces cell death in a dose and time dependent manner on K-562 cells. It is found that the effect was improved linearly while prolonging the incubation time. Compared to the cell cycle profiles of untreated cells, flow cytometric analysis indicated the sub-G1 arresting effect of ruthenium compound on K-562 cells. In our study, {*cis*-[Ru(C₂O₄)(NH₃)₄] $_2$ (S₂O₆)} shows a significant increase in tailed cells in any of the concentrations tested compared with negative control. Consequently, the concentration of {*cis*-[Ru(C₂O₄)(NH₃)₄]₂(S₂O₆)} might be associated cytotoxicity with direct effect on K-562 cells DNA. Thus, it can be deducted that ruthenium-based compounds present selectivity to enter both tumor and normal cells. Additional studies are needed to determine the molecular mechanisms of the active components and to evaluate the potential in vivo anticancer activity of the *cis*-tetraammine(oxalato)ruthenium(III) dithionate.

Keywords: *cis*-tetraammine(oxalato)ruthenium(III) dithionate; Cytotoxic activity; K-562; Ruthenium(III) compounds; Immunomodulatory activity; Apoptosis

1. Introduction

Leukemia is a major type of cancer affecting a significant segment of the population, and especially children. In fact, leukemia is the most frequent childhood cancer, with 26% of all cases, and 20% mortality (Canadian Cancer Society/National Cancer Institute of Canada 2005). The American Cancer Society (ACS) estimated that 47,150 new cases of leukemia would be diagnosed in the United States in 2012, whereas about 23,540 adults and children would die of leukemia during 2012 (American Cancer Society 2009).

* Correspondence: silveiralacerda@gmail.com

¹Laboratório de Genética Molecular e Citogenética, Instituto de Ciências Biológicas, Universidade Federal de Goiás - UFG, Campus Samambaia (Campus II), Cx. Postal: 131, Goiânia, GO 74001-970, Brazil Full list of author information is available at the end of the article Although the incidence rate for this disease remains relatively unchanged, some success has fortunately been attained in its treatment. But even if the success of clinical trials in identifying new agents and treatment modalities has been significant, current treatments have many limitations related to their side effects and the development of acquired drug resistance (Robert and Jarry 2003) The new therapeutic agents thus needed should be more active and produce less side effects and they also should act through a mechanism different from that of cytotoxic agents already used (Menezes et al. 2007; Silveira-Lacerda et al. 2009).

Chemotherapy is a common treatment for leukemia (Ge et al. 2009). In general the therapy uses a number of different anticancer drugs, which destroy cancer cells by preventing them from growing and dividing rapidly. Unfortunately, a number of the body's normal, non-



© 2014 Pereira et al.; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. cancerous cells (e.g., hair cells, red and white blood cells, blood-clotting platelets, and cells of the gastrointestinal mucosa) also divide rapidly and are harmed by chemotherapy (Ge et al. 2009; Kim et al. 2002). The side effects of chemotherapy hamper many normal activities of patients undergoing treatment (Kim et al. 2002).

The preparations of metallo complexes with potential antitumor activity has been one of the main targets of transition metal chemistry since Rosenberg's discovery of cisplatin {*cis*-diamminedichloridoplatinum(II), *cis*-[Pt(NH₃) $_{2}Cl_{2}$ cytotoxic activity in the 1960s (Rosenberg et al. 1965). In 1978, cisplatin was approved as the first platinum based drug for the oncology treatment, although several negative side-effects (nephrotoxicity, neurotoxicity, nausea, etc.) had been induced on treated patients (Kelland and Farrell 2000). Nevertheless, cisplatin was followed by carboplatin {cis-diammine-1,1' -cyclobutanedicarboxylate platinum(II), [Pt(NH₃)₂(cbdc)], approved in 1985} and oxaliplatin {1R,2R-diamminocyclohexaneoxalatoplatinum(II), [Pt(dach)(ox)], approved in 1996}, which met requirements of improving antitumor activity and reducing disadvantages of cisplatin, carboplatin and oxaliplatin represent the second, and third platinum-based drug generations, respectively ((Kelland and Farrell 2000; Starha et al. 2009). Nowadays, not only platinum-bearing complexes are extensively studied with the aim to broaden a spectrum of transition metal-based complexes which could be used in the treatment of cancer (Starha et al. 2009).

In addition to the other metal complexes cisplatin have been developed using heavy metals. For example, gold complexes have been developed for the treatment of rheumatoid arthritis, silver complexes as anti-microbial agents, antimony complexes for the treatment of leishmaniasis, vanadium(IV) complexes as antiviral and antidiabetic agents, arsenic trioxide (Trisenox) for the treatment of acute promyelocytic leukaemia, and metalactivated bleomycin for the treatment of Hodgkin's lymphoma and testicular cancer. Transition-metal-based therapeutic agents currently under clinical trials include third generation antitumor platinum complexes such as liposomal cisplatin (Lipoplatin), satraplatin, and picoplatin, the antimalarial ferrocene–quinoline conjugate ferroquine (Lung et al. 2013).

Rhodium and Iridium has also been used for the synthesis of these metal complexes, as they allow greater selectivity and affinity molecules. The iridium (III) already shows results inhibiting TNF- α in HepG2 line through a hydrophobic binding (Meggers 2009; Leung et al. 2012). These metal complexes possess many advantages that make them suitable for the development of new therapeutic agents and compounds of ruthenium has been highlighted because ruthenium complexes have shown potential utility in chemotherapy and photodynamic therapy (Clarke 2003; Ronconi and Sadler 2007). Ruthenium complexes generally have lower toxicities compared to cisplatin attributed to their specific accumulation in cancer tissues (Sava et al. 1998). *In vitro* and in vivo studies show high anticancer activity of ruthenium complexes and some of them are currently undergoing clinical trials (Jakupec et al. 2005; Hartinger et al. 2006).

The identification of new chemotherapeutics agents is critical for further progress in the treatment of leukemia. In comparison to the platinum(II) antitumor complexes currently used in the clinic, ruthenium compounds offer potentially reduced toxicity, a novel mechanism of action, the prospect of non-cross-resistance, and a different spectrum of activity (Clarke 2003). The reduced toxicity is in part due to the ability of ruthenium complexes to mimic the binding of iron to molecules of biological significance, exploiting the mechanisms that the body has evolved for non-toxic transport of iron (Frasca et al. 2001). This reduced toxicity, together with noncross-resistance in cisplatin-resistant cancer cells, is particularly attractive attributes of these complexes (Allardyce et al. 2003).

Based on these evidences, in the present work we studied the cytotoxic activity of the ruthenium(III) compound *cis*-tetraammine(oxalato)ruthenium(III) dithionate {*cis*-[Ru(C₂O₄)(NH₃)₄]₂(S₂O₆)} against human chronic myelogenous leukemia (K-562) tumor cell line.


2. Results

2.1 The cis-[Ru(C₂O₄)(NH₃)₄]₂(S₂O₆) compound reduces viability of K-562 cells

Results derived from Trypan blue staining essay revealed that K-562 cells cultured with concentrations 40 and 150 μ M of ruthenium(III) compound showed significant reduction of proliferation after 72 h of exposition, with viabilities ranging from 88.2% to 55.6% when treated with 40 μ M for 24 and 72 h; and 76.2% to 26.7% when treated with 150 μ M for 24 and 72 h Figure 1.

2.2 The cis-[Ru(C₂O₄)(NH₃)₄]₂(S₂O₆) compound presents cytotoxic activity towards K-562 tumor cell lines

To verify the cytotoxic activity of *cis*-[Ru(C_2O_4)(NH₃)₄]₂ (S₂O₆) on K-562 cell lines, tumor cells were cultured for 24 and 48 h in the presence of different concentrations of ruthenium compound. MTT reduction assay revealed that ruthenium compound produced concentration and time-dependent cytotoxicity effects on K-562 cells. The results Figure 2b show that the ruthenium(III) compound induced low [22.4% (24 h) to 28.2% (48 h) and 29.8% (24 h) to 35.7% (48 h) for concentrations 10 and 40 μ M, respectively] to up [44% (24 h) and 53% (48 h) for concentration 150 μ M] of cytotoxic activity against K-562. After incubation for 48 h, the IC₅₀ value was 18.28 μ M (Figure 2a).




2.3 The cis-[Ru(C₂O₄)(NH₃)₄]₂(S₂O₆) induced apoptosis in K-562 cells as verified by DNA ladder analysis

The significantly reduced number of K-562 cells in the presence of *cis*-tetraammine(oxalato)ruthenium(III) dithionate on previous assays suggests that this compound could be inducing cell death via apoptosis. To examine proapoptotic properties of the ruthenium(III) compound, K-562 cells were cultured in the presence of different concentrations of ruthenium compound (from 0.15–150 μ M) and then DNA ladder analysis was performed via agarose gel electrophoresis. K-562 cells cultured in

the presence of ruthenium compound but not in medium alone presented DNA fragmentation (Data not shown).

2.4 The cis-[Ru(C₂O₄)(NH₃)₄]₂(S₂O₆) presents genotoxic effects against K-562 tumor cells

The alkaline comet assay has been used to assess the possible genotoxicity of *cis*-tetraammine(oxalato)ruthenium (III) dithionate against K-562 cells. Results indicate that K-562 tumor cells cultured with ruthenium(III) complex show a significant increase in DNA damage index



in any of the concentrations tested compared with negative control, in a dose-dependent manner (Figure 3). Results show an average DNA damage index of 59 for 10 μ M, 140 for 40 μ M, 176 for 150 μ M when K-562 tumor cells were exposed to ruthenium(III) for 24 h; and 108 for 10 μ M, 154 for 40 μ M and 197 for 150 μ M, for 48 h of exposition. Thus, the concentration of *cis*-[Ru(C₂O₄)(NH₃)₄]₂(S₂O₆) might be associated cytotoxicity with direct effect on K-562 cells DNA (p < 0.05).


2.5 The cis-[Ru(C₂O₄)(NH₃)₄]₂(S₂O₆) increased the number of K-562 tumor cells in sub-G1 phase, an indicative of apoptosis


The cell cycle distribution of K-562 cells treated with different concentrations of ruthenium compound (from 1.5-150 µM) for 24, 48 and 72 h revealed a prominent increasing of cells on sub-G1 phase at concentration 40 and 150 µM and reduction on G0/1, S and G2/M phases. Figure 4 shows that treatment with 40 and 150 μ M of *cis*-[Ru(C₂O₄)(NH₃)₄]₂(S₂O₆) for 24, 48 and 72 h caused an increase in the proportion of cells in the sub-G1-peak correlating with fewer cells in G0/G1, S and G2/M. The fraction of sub-G1 cells increased from 14.5% in the control to 59% at 24 h; 10.7% in the control to 68.6% at 48 h; 15.5% in the control to 84.7% for 72 h on cells treated with 40 µM of *cis*-tetraammine(oxalato) ruthenium(III) dithionate. The same effect was observed when K-562 tumor cells were treated with 150 µM of ruthenium(III) compound. The ruthenium(III) compound caused a minor S phase accumulation after incubation at concentrations of 40 and 150 µM for all periods of exposition Table 1.

3 Discussion

Apoptosis is an active physiological process resulting in cellular self-destruction that involves specific morphological and biochemical changes in the nucleus and cytoplasm (Kostova 2006). Agents that suppress the proliferation of malignant cells by inducing apoptosis may represent a useful mechanistic approach to both cancer chemoprevention and chemotherapy. While many anticancer agents have been developed, unfavourable side effects and resistance are serious problems (Panchal 1998). Since the introduction of cisplatin in cancer therapy, metal complexes and organometallic compounds have been gaining importance in oncology (Panchal 1998; Sanna et al. 2002). Metalbased compounds increase the possibility of developing molecules better-suited for binding to specific biological targets (Sanna et al. 2002; Hartinger et al. 2006).

Ruthenium complexes appear particularly promising; although they exhibit lower cytotoxicity as compared to cisplatin, they are better tolerated in vivo (Sanna et al. 2002; Hartinger et al. 2006; Menezes et al. 2007). Research on bioactive ruthenium(II) complexes is very active (Chen and Wong 2008). These studies have led to the development of ruthenium based anticancer agents (Yan et al. 2005; Ang and Dyson 2006; Hartinger et al. 2006). Research groups of Sadler, Dyson, Keppler and Reedijk have synthesized a remarkably large number of Ru(II)/Ru(III) organometallic complexes that are being tested for anticancer activity. Ruthenium complexes are slitly cytotoxic but do not affect normal cells significantly. Ruthenium drugs are very promising candidates for novel cancer therapy, with two drugs already in clinical trials, NAMI-A and KP1019 (Cocchietto and Sava 2000; Zorzet et al. 2001;





Hartinger et al. 2006). Thus, there is growing interest in the use of new organometallics for the treatment of various cancers and the development of safer and more effective therapeutic agents (Panchal 1998; Silveira-Lacerda et al. 2009). In the present work, we studied the cytotoxic activity of *cis*-tetraammine(oxalato)ruthenium(III) dithionate cytotoxicity towards human chronic myelogenous leukemia (K-562) tumor cell line.

The antiproliferative activity of *cis*-tetraammine(oxalato) ruthenium(III) dithionate, a ruthenium-based complex, have been evaluated *in vitro* against human leukemia (K-562)

cells using trypan blue and MTT assay. Inhibition of cell proliferation is an important potency indicator for chemotherapeutic drugs. As shown in Figures 1 and 2a and b, the tested compound induces cell death in a dose and time dependent manner on K-562 cells. It is found that the effect was improved linearly while prolonging the incubation time. The determined IC₅₀ values of this complex, 18.28 μ M (Figure 2a), is considerably the same of those of the commercially used antineoplastic drugs cisplatin (IC₅₀ = 11 μ M) and oxaliplatin (IC₅₀ = 18 μ M) on the same tumor cell line (Štarha et al. 2009). These results corroborate previous

	Control	Ru 1.5 μM	Ru 10 μM	Ru 40 μM	Ru 150 μM
24 h	Mean ± S.D.	Mean ± S.D	Mean ± S.D	Mean ± S.D	Mean ± S.D
Sub-G0/G1	14.45 ± 0.6	30.20 ± 2.1	31.20 ± 1.4	59.00 ± 2.3	68.90 ± 1.8
G1	27.20 ± 0.3	25.25 ± 2.1	19.55 ± 0.9	11.50 ± 1.7	14.75 ± 0.9
S	19.05 ± 0.1	27.50 ± 1.1	29.10 ± 1.1	18.60 ± 2.1	11.40 ± 0.8
G2	14.10 ± 0.1	14.85 ± 0.8	18.10 ± 0.7	9.15 ± 1.6	4.00 ± 0.1
48 h					
Sub-G0/G1	10.70 ± 0.7	24.65 ± 1.1	40.55 ± 2.6	68.60 ± 1.1	67.60 ± 0.1
G1	35.65 ± 0.6	31.70 ± 1.0	14.85 ± 2.6	8.35 ± 0.4	19.30 ± 0.4
S	21.35 ± 0.4	30.05 ± 0.8	26.35 ± 2.1	14.35 ± 0.9	9.75 ± 0.2
G2	10.00 ± 1.4	12.50 ± 0.3	17.05 ± 2.3	7.85 ± 0.1	2.95 ± 0.1
72 h					
Sub-G0/G1	15.50 ± 16.0	34.50 ± 1.4	45.95 ± 1.1	84.70 ± 0.3	70.50 ± 2.8
G1	35.45 ± 10.1	31.75 ± 0.5	17.05 ± 0.2	4.95 ± 0.1	18.70 ± 1.0
S	20.05 ± 4.7	23.80 ± 0.6	26.05 ± 0.6	7.20 ± 0.6	9.25 ± 1.6
G2	7.45 ± 0.8	9.30 ± 0.4	10.50 ± 0.3	3.10 ± 0.1	1.45 ± 0.2

Table 1 Cell cycle analysis of K-562 tumor cell lines after treatment with cis-tetraammine(oxalato)ruthenium(III) dithionate

The percentage of cells in G0/G1, S, G2/M and sub-G1 was analyzed using ModFit LT software (Verity Software House, Topsham, ME, USA). Percentage of viable cells at each phase of the cell cycle (G0/G1, S, G2/M). Data represent mean values \pm SD of triplicate samples or a histogram for each condition and cell type. The results shown are representative of at least three similar experiments. *p < 0.05 vs. control.

observations that r(III) complexes induces cytotoxicity towards tumor cells such as human Jurkat, HeLa and SK-BR-3, and murine S-180 and A-20 tumor cell lines (Frasca et al. 2001; Silveira-Lacerda et al. 2009).

For ruthenium(II) complexes as methylimidazole (RMC1) he also found having cytotoxicity of 17.34 mg mL⁻¹ for A549, 18.89 mg mL⁻¹ for A375 and 20.25 mg mL⁻¹ for Hep G2, respectively. The same compound exhibits cytotoxicity of 51.59 mg mL⁻¹ for HBE (basal lineage), as well as demonstrating that the compound RMC1 ruthenium II (Yang et al. 2012). The complex [Ru(phen)₂(β -MOPIP)]²⁺ can effectively inhibit proliferation of the A375 cell line with a low IC₅₀ (5.9 ± 1.1 mM). [Ru(bpy)₂(dppn)]²⁺ exhibits high cytotoxicity against human HT-29 and MCF-7 cancer cell lines comparable to that of cisplatin induces cell death in a dose and time dependent manner (Schatzschneider et al. 2008), and [Ru(dmp)₂(DBHIP)]²⁺ can effectively induce apoptosis of the BEL-7402 cell line (Liu et al. 2010).

The lower general toxicity of ruthenium compounds compared to platinum drugs has been attributed to the ability of ruthenium compounds to specifically accumulate in cancer tissues. The higher specificity of these compounds for their targets may also be linked to their selective uptake by the tumor compared with healthy tissue and to selective activation by reduction to cytotoxic species within the tumor (Bergamo et al. 1999; Allardyce et al. 2003; Clarke 2003).

Ruthenium-chloro complexes tend to undergo hydrolysis in aqueous media leading to the generation of cationic $Ru-OH_2$ complexes capable of reacting with DNA with greater ease than the corresponding chloro complexes (Melchart et al. 2007; Bacac et al. 2004; Hotze et al. 2004). The hydrolyzed complexes interact with the N7 of guanine in DNA duplexes leading to disruption of the structure of genetic material (Chen et al. 2003).

To explore the mechanisms of the cytotoxic effects produced by *cis*-tetraammine(oxalato)Ruthenium(III) dithionate, drug-induced changes in cell cycle distribution were examined. Compared to the cell cycle profiles of untreated cells, flow cytometric analysis indicated the sub-G1 arresting effect of ruthenium compound on K-562 cells, as ruthenium (III) dithionate already induced a 48.2% increase in the number of sub-G0/G1 cells after a 48 h incubation. The ruthenium(III) compound caused a minor S phase accumulation after incubation at concentrations of 40 and 150 μ M for all periods of exposition Figure 4. Treatment with 40 μ M of *cis*-[Ru(C₂O₄)(NH₃)₄]₂(S₂O₆) induced respectively a 1.7-fold, 2.2-fold and 2.4-fold increase in the number of sub-G0/G1 cells when compared to control for 24, 48 and 72 h, respectively Table 1.

Furthermore, another important biochemical sign of apoptosis was studied: DNA laddering and fragmentation (data not shown), possibly representing DNA cleavage into oligonucleosomal fragments through activation of the cysteine protease caspase-3, which is involved in the proteolytic cleavage of key downstream proteins such as poly (ADP-ribose) polymerase (PARP) (Bortner et al. 1995; Clarke and Stubbs 1996). This process ultimately results in DNA fragmentation and apoptotic death (Bortner et al. 1995). Although this type of binding has been suggested to mimic, to some extent, cisplatin-induced DNA crosslinking, other types of damage may exist that dominate or contribute to the biological activity of this drug prototype.

Several studies have been using this test to corroborate the results obtained in other assays. In the present study, results derived from DNA laddering assay did not show K-562 DNA fragmentation, instead the results shows DNA integrity and even differences on DNA content. Is important note that this data does not corroborate with more sensitive techniques such as flow cytometry and comet assay, used in this work. These techniques confirmed that the ruthenium(III) compound interfere on cell cycle and induces cells to enter apoptosis. Thus, we can infer that the technique of DNA gel electrophoresis is not best assay to assess the degradation of genome DNA.

The present study also evaluated the DNA-damaging effects detected by the alkaline version of the comet assay in K-562 cancer cells. This assay has been used as a test to predict the risk to develop certain diseases (renal cell carcinoma, cancers of the bladder, esophagus, and lung) due to susceptibility of the individual to DNA damage (Ribeiro et al. 2009). The *in vitro* comet assay is proposed as an alternative to cytogenetic assays in early genotoxicity/ photogenotoxicity screening of drug candidates as well as for neurotoxicity (Witte et al. 2007).

The alkaline comet assay has been used to assess the genotoxicity of chemicals, environmental exposures to carcinogens, toxins, and physical agents both *in vitro* and in vivo (Trzeciak et al. 2000; Sekihashi et al. 2002). This method was also used to measure DNA repair capacity in live cells (Banath et al. 1998) and acellular systems (Dusinská et al. 2004).

In our study, cis-[Ru(C₂O₄)(NH₃)₄]₂(S₂O₆) shows a significant increase in tailed cells in any of the concentrations tested compared with negative control (Figure 3). Consequently, the concentration of cis-[Ru(C₂O₄)(NH₃)₄]₂ (S_2O_6) might be associated cytotoxicity with direct effect on K-562 cells DNA. Thus, it can be deducted that ruthenium-based compounds present selectivity to enter both tumor and normal cells. It is known that all the body cells present transferrin receptors, particularly tumor cells, in which these receptors are found in higher numbers. Due to these features, higher quantities of ruthenium complexes penetrate tumor tissue, reduce ruthenium(III) to ruthenium(II) and binding to DNA (guanine), and promote strand breaks (Clarke and Stubbs 1996; Lebwohl and Canetta 1998; Sava and Bergamo 2000; Katsaros and Anagnostopoulou 2002; Galanski et al. 2003; Desoize 2004). Another hypothesis is that even in small quantities this compound might enter normal cells, because ruthenium (III) complexes are activated only by its reduction when it finds an environment with high concentration of glutathione, low pH, and occurrence of hypoxia. It is very common to find tumor cells presenting these conditions since it is known that these cells have high levels of glutathione and oxygen consumption when the nutrients are quickly used due to their accelerated development promoting hypoxia (Sava and Bergamo 2000). Consequently, these cells need more glycolitic energy, which increases the level of lactic acid in the tissues and causes a decrease in the media pH. It is worth emphasizing that ruthenium(III) compounds can be used as pro-drugs that are activated by in vivo reduction to ruthenium(II) (Desoize 2004; Sava and Bergamo 2000).

Broadening the chemotherapeutic arsenal depends on understanding existing agents with a view toward developing new modes of attack. Indeed, few of the organometallics compounds may function in a manner analogous to cisplatin, which appears to bend DNA by cross-linking adjacent guanines, thereby causing a class of DNA binding proteins to adhere to the site. Overall, the broad class of ruthenium(III) antitumor agents appears to differ from cisplatin by favoring interstrand rather than intrastrand cross-links (Clarke et al. 1999). In agreement with this hypothesis, it was demonstrated that NAMI-A induced apoptosis in the ECV304 transformed human endothelial and KP1019 in colorectal carcinoma cell lines via activation of caspase-3 and DNA fragmentation (Bortner et al. 1995; Nunez et al. 1998; Kapitza et al. 2005).

Despite the resounding success of cisplatin and closely related platinum antitumor agents, the movement of other transition-metal antitumor agents toward the clinic has been exceptionally slow (Clarke et al. 1999). Non-Platinum chemotherapeutic metallopharmaceuticals hold much pro mise for the future, and needs to be actively explored in a large variety of tumor types in combination therapies. Besides the already well established NAMI-A and KP-1019 activities on gastrointestinal, breast, prostate, and ovarian cancers (Pluim et al. 2004; Bergamo and Sava 2007), development as a potential anti-tumor drug.

4 Conclusions

The present results indicate that cis-[Ru(C₂O₄)(NH₃)₄]₂ (S₂O₆) is worthy of further development as a potential antitumor drug that could be used in the treatment of leukemia. Thus, additional studies are needed to determine the molecular mechanisms of the active components and to evaluate the potential in vivo anticancer activity of the *cis*-tetraammine(oxalato)ruthenium(III) dithionate.

5 Material and methods


5.1 Synthesis of *cis*-[Ru(C_2O_4)(NH₃)₄]₂(S_2O_6)

The *cis*-[Ru(C₂O₄)(NH₃)₄]₂(S₂O₆) complex (Figure 5), was synthesized at the Universidade Federal de Uberlândia (UFU, Minas Gerais, Brazil) following a standard protocol described by Pereira et al. (2009). The compound was characterized by electronic spectra at room temperature with the HP 8453 spectrophotometer with diodes arrangement, interfacing a compatible PC HP Vectra XM, using quartz cells. Carbon and hydrogen microanalyses were performed by the staff of the Analitical Centre of the Chemistry Institute of Universidade de São Paulo (USP, São Paulo, Brazil).

5.2 Cell culture

The human chronic myelogenous leukemia (K-562) cell line (ATCC number CCL-243^m) was obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). The cells were cultured in RPMI 1640 medium (pH 7.2–7.4) supplemented with 100U mL⁻¹ penicillin G, 100 µg mL⁻¹ streptomycin, 2 mM L-glutamine, 1.5 g L⁻¹ sodium bicarbonate, 4.5 g L⁻¹ glucose, 10 m*M* HEPES, 1.0 m*M* sodium pyruvate and 10% fetal calf serum (FCS) (all reagents were obtained from Gibco, Grand Island, NY, USA) at 37°C, 5% CO₂ and humidified atmosphere.

The cells were disposed into 96 well plates $(1 \times 10^5 \text{ cells}/\text{ well})$ and cultured in RPMI 1640 medium. Cells were harvested at specified intervals and the number of cells per well was determined by cell counting with a hemo-cytometer (Neubauer chamber). Briefly, tumor cells were aspirated, washed in sterile PBS and an aliquot of the cell suspension was put in Trypan Blue 1% (m/v) (Sigma-



Aldrich, St. Louis, MO, USA) and counted. Only cell dilutions with > 95% of viable cells were included in the posteriors analysis.

5.3 Cell citotoxicity (Trypan blue staining)

The citotoxicity of the K-562 cells was evaluated by the trypan blue exclusion assay. The tumor cells were incubated for 24 h, 48 h and 72 h with different concentrations of the tested ruthenium compound cis-[Ru(C₂O₄)(NH₃)₄]₂(S₂O₆) (from 0.015-32 µM) at 37°C. Additionally, Carboplatin (50 μ M) and Paclitaxel (25 μ M) were applied as positive control. After incubation, the cells were washed in PBS (pH 7.4) and suspended in a complete RPMI 1640 medium. Then 40 μ L of the trypan blue solution (0.4%, Sigma) and 10 µL of the cell suspension were mixed and after 5 min the percentage of viable K-562 cells was evaluated under brightfield optical microscope using a newbauer chamber. The correlation between the viable cells (that excluded trypan blue dye) and dead cells (stained cells) were assessed. The results are presented as mean \pm S.D. (standard deviation) from three independent experiments.

5.4 Viability assay

Cytotoxic activity of cis-[Ru(C₂O₄)(NH₃)₄]₂(S₂O₆) on K-562 was measured by modified MTT assay (Mosmann 1983), which is based on the reduction of yellow 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) to dark-blue, insoluble formazan in mitochondria of the living cells. The MTT assay was performed in 96-well tissue culture plates (Nalge-Nunc, Rochester, NY, USA) as follows: the cells $(1 \times 10^5/\text{well})$ were seeded in tissue culture plates and incubated with the different concentrations of ruthenium compound (from 0.15-150 µM) dissolved in a total volume of 100 µL/well for 24 h and 48 h at 37°C and 5% CO₂. The cells incubated with medium only served as a control. Following the exposure to the tested substances, the cells were incubated with 10 µL of MTT solution (5 mg mL⁻¹) (Sigma-Aldrich, St. Louis, MO, USA) for 3 h. The microplates were then centrifuged $(300 \times g/15 \text{ min}/10^{\circ}\text{C})$ and the culture media were discarded. Afterwards 200 μl of PBS/20% of SDS (lauryl sulfate) solution (Sigma-Aldrich, USA) was added to each well to stop the reaction and plates were kept in the dark overnight. After the next 12 h, the absorbance of dissolved formazan was measured by a Stat Fax 2100 microplate reader (Awareness Technology, Palm City, FL, USA) at 565 nm. The cell viability was expressed in% related to control (100% of viability). The cytotoxic rate was calculated as follows: cytotoxicity (%) = [1 - (absorbance of the treated wells) / (absorbance of thecontrol wells)] \times 100%. The cytotoxic effect of the tested substances was determined in at least three independent experiments, where each one of the culture plates contained the wells with tested concentration in triplicate, the wells with control (cells in medium) and the blank (culture medium alone). The 50% inhibitory concentration (IC_{50}) value was determined using GraphPad Prism 4.02 for Windows (GraphPad Software, San Diego, CA, USA).

5.5 DNA laddering assay

Briefly, 2×10^6 cells (K-562) were treated with different concentrations of *cis*-[Ru(C₂O₄)(NH₃)₄]₂(S₂O₆) (from 0.15-150 μ M) for 24 h at 37°C and 5% CO². Cells were harvested and centrifuged at $300 \times g/15 \text{ min}/10^{\circ}\text{C}$ and washed with PBS. The cells were then ressuspended at a concentration of 1×10^{6} cells mL⁻¹ in an extraction buffer (1 mol Tris-HCl, 2 mol Na₂EDTA, 0,5 g m L⁻¹ SDS) and treated with 20 mg L⁻¹ RNase A at 37°C for 60 min, followed by incubation with proteinase K (100 mg L^{-1}) at 37°C for 60 min. An equal volume of saline solution (NaCl 6 M) was added to the cells and centrifuged at $13,000 \times g$ for 10 min. The supernatant was collected and 2 volume ethanol (-20°C) were added. The samples were centrifuged at $13,000 \times g$ for 30 min at 4°C. The supernatant was then discarded and the pellets dissolved in TE buffer $(1\times)$. The concentration of DNA was detected using a UV spectrophotometer (Beckman DU-640, USA). The DNA (5 µg/tube) was transferred to a 1.5% agarose horizontal gel, and electrophoresis was performed at 100 V cm⁻¹ for 90 min. The DNA in the gels was visualized by ultraviolet transillumination after staining with ethidium bromide (5 μ g mL⁻¹) using an Omega[®] molecular imaging system (UltraLum Inc., Claremont, CA, USA).

5.6 Comet assay

An aliquot of from each K-562 culture was taken after 24 and 48 h incubation for the alkaline version of the comet assay (Ribeiro et al. 2009). The compound cis-[Ru(C₂O₄) $(NH_3)_4]_2(S_2O_6)$ was studied at different concentrations (from 10–150 μ M). Briefly, 300 μ L of the cell suspension was centrifuged for 5 min (500 rpm) in a refrigerated microcentrifuge (Sorvall Legend Mach 1.6 R, Thermo Fisher Scientific, Waltham, MA, USA). The resulting pellet was homogenized with 80 µL of a low melting point agarose (0.5%), spread onto microscope slides pre-coated with a normal melting point agarose (1.5%), and covered with a cover slip. After 5 min at 4°C, the cover slip was removed, and the slides were immersed in cold lysis solution [2.4 M NaCl, 100 mM ethylenediamine tetraacetic acid (EDTA), 10 mM Tris, 10% DMSO, and 1% Triton-X, pH 10] for 24 h.

After lysis, the slides were placed in an electrophoresis chamber and covered with electrophoresis buffer (300 mM NaOH per 1 mM EDTA, pH > 13) for a remaining 20 min to allow DNA unwinding. The electrophoresis proceeded for 20 min (25 V and 300 mA). Afterwards, the slides were submerged for 15 min in a neutralization buffer (0.4 M Tris– HCl, pH 7.5), dried at room temperature, and fixed in 100% ethanol for 5 min. All the steps were conducted in

the dark to prevent additional DNA damage. Slide staining was performed immediately before analysis using ethidium bromide (20 µg mL⁻¹). Slides were prepared in duplicate, and 100 cells were screened per sample (50 cells from each slide) in a fluorescent microscope (Leica Microsystems GmbH, Wetzlar, Germany) equipped with an excitation filter of 515-560 nm and a barrier filter of 590 nm using a \times 40 objective. The analyse nucleus was realized in image analysis system software CometScore 15 according to the migration of the fragments, as previously proposed as follows: class 0 (no damage); class 1 (little damage with a short tail length smaller than the diameter of the nucleus); class 2 (medium damage with a tail length one or two times the diameter of the nucleus); class 3 (significant damage with a tail length between two and a half to three times the diameter of the nucleus); and class 4 (significant damage with a long tail of damage greater than three times the diameter of the nucleus). A value (damage index, DI) was assigned to each comet according to its class, according to the following formula:

 $DI = (0 \times n_0) + (1 \times n_1) + (2 \times n_2) + (3 \times n_3) + (4 \times n_4)$, where n = number of cells in each class analysed.

DI thus ranged from 0 (completely undamaged: 100 cells \times 0) to 400 (with maximum damage; 100 cells \times 4).

5.7 Cell cycle analysis by flow cytometry

In order to investigate the possible effect of the ruthenium compound on cell cycle progression, K-562 cells were treated with different concentrations of *cis*-[Ru(C₂O₄)(NH₃) 4]₂(S₂O₆) (from 1.5–150 μ M) for 24, 28 and 72 h. Briefly, 5×10^5 cells were harvested by centrifugation, washed with PBS, fixed with 70% (v/v) cold aqueous ethanol and stored overnight at -20°C. The fixed cells were washed with PBS and incubated with propidium iodide (PI; Sigma-Aldrich, St. Louis, MO, USA) containing 0.05% RNase. Samples were incubated at 4°C in the dark and analyzed by flow cytometry (FACS CantoII, BD Biosciences, San José, CA, USA). The percentage of cells in G1, S, G2 and sub-G1 was analyzed using ModFit LT software (Verity Software House, Topsham, ME, USA).

5.8 Statistical analysis

Three independent *in vitro* experiments were carried out. Statistical results were expressed as the mean ± standard deviation of the means obtained from triplicates of each independent experiment. Correlation tests were performed to determine the effects of concentration of ruthenium complex on tumor cell lines. Statistical significance of differences *(p < 0.05) as compared to untreated cells (control) was evaluated by applying analysis of variance (ANOVA) and Tukey or Dunnet's post tests, when applicable. The IC₅₀ (concentration that produces a 50% inhibitory effect on the evaluated parameter) was graphically obtained from the dose–response curves.

Ethical Approval

No studies involving humans or experimental animals were conducted in this work. The human chronic myelogenous leukemia (K-562) cells were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA) and cultured in vitro.

Competing interests

There are no financial or personal interests that might be viewed as inappropriate influences on the work presented herein. This manuscript was completely financed by governmental and nonprofit institutions, the Brazilian National Counsel of Technological and Scientific Development (CNPq), Research and Projects Financing (FINEP), Coordination for the Advancement of Higher Education Staff (CAPES) and Foundation for the Support of Research in the State of Goias (FAPEG).

Authors' contributions

The work presented here was carried out in collaboration between all authors. EPSL defined the research theme. FCP, APL, CASTVC, ASBBR and EPSL designed methods and experiments. FCP, APL, CASTVC, WCP, ASBBR and LCGP carried out the laboratory experiments. FCP, APL, CASTVC and EPSL analyzed the data and interpreted the results. FCP, CASTVC and EPSL wrote the paper. LAP and WBS synthesized the Ruthenium(III) compound. All authors have contributed to, seen and approved the manuscript.

Acknowledgments

The authors gratefully acknowledge the financial support of Research and Projects Financing (FINEP) (Grant No. 01.06.0941.00/CT-Saúde to Elisângela de Paula Silveira-Lacerda) and Foundation for the Support of Research in the State of Goias (FAPEG). Coordination for the Advancement of Higher Education Staff (CAPES) through fellowship to Flávia de Castro Pereira, Cesar Augusto Sam Tiago Vilanova-Costa, Wanessa Carvalho Pires and Lucas Carlos Gomes Pereira, and Brazilian National Council of Technological and Scientific Development (CNPq) through fellowship to Aliny Pereira de Lima (Grant No. 141648/2010-4).

Author details

¹Laboratório de Genética Molecular e Citogenética, Instituto de Ciências Biológicas, Universidade Federal de Goiás - UFG, Campus Samambaia (Campus II), Cx. Postal: 131, Goiânia, GO 74001-970, Brazil. ²Instituto de Química, Universidade Federal de Uberlândia - UFU, Uberlândia MG 38400-902, Brazil. ³Instituto de Ciências Exatas e da Terra, Universidade Federal de Mato Grosso - UFMT, Barra do Garças MT 78698-000, Brazil.

Received: 13 December 2013 Accepted: 23 April 2014 Published: 19 June 2014

References

- Allardyce CS, Dyson PJ, Ellis DJ, Salter PA, Scopelliti R (2003) Synthesis and characterisation of some water soluble ruthenium(II)–arene complexes and an investigation of their antibiotic and antiviral properties. J Organomet Chem 668:35–42
- American Cancer Society (2009) Cancer facts & figures. http://www.cancer.org/ acs/groups/content/@nho/documents/document/500809webpdf.pdf
- Ang WH, Dyson PJ (2006) Classical and non-classical ruthenium-based anticancer drugs: towards targeted chemotherapy. Eur J Inorg Chem 2006:4003–4018
- Bacac M, Hotze ACG, Schilden KVD, Haasnoot JG, Pacor S, Alessio E, Sava G, Reedijk J (2004) J Inorg Biochem 98:402–412
- Banath JP, Fushiki M, Olive PL (1998) Rejoining of DNA single- and double-strand breaks in human white blood cells exposed to ionizing radiation. Int J Radiat Biol 7:649–660
- Bergamo A, Sava G (2007) Ruthenium complexes can target determinants of tumour malignancy. Dalton Trans 13:1267–1272
- Bergamo A, Gagliardi R, Scarcia V, Furlani A, Alessio E, Mestroni G, Sava G (1999) *In vitro* cell cycle arrest, in vivo action on solid metastasizing tumors and host toxicity of the antimetastatic drug NAMI-A and cisplatin. J Pharmacol Exp Ther 289:559–564
- Bortner CD, Oldenburg NB, Cidlowski JA (1995) The role of DNA fragmentation in apoptosis. Trends Cell Biol 5:21–26
- Canadian Cancer Society/National Cancer Institute of Canada (2005) Canadian cancer statistics. ISSN, Toronto, Canada, pp 0835–2976

Chen T, Wong YS (2008) Selenocystine induces apoptosis of A375 human

melanoma cells by activating ROS-mediated mitochondrial pathway and p53 phosphorylation. Cell Mol Life Sci 65:2763–2775 Chen H, Parkinson JA, Morris RE, Sadler PJ (2003) J Am Chem Soc 125:179–186

Clarke MJ (2003) Ruthenium metallopharmaceuticals. Coordination Chemistry Review 236:209–233

Clarke MJ, Stubbs M (1996) Interactions of metallopharmaceuticals with DNA. Met Ions Biol Syst 32:727–780

Clarke MJ, Zhu F, Frasca DR (1999) Non-platinum chemotherapeutic metallopharmaceuticals. Chem Rev 99:2511–2534

Cocchietto M, Sava G (2000) Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice. Pharmacol Toxicol 87:193–197

Desoize B (2004) Metals and metal compounds in cancer treatment. Anticancer Res 24:1529–1544

Dusinská M, Collins A, Kazimírová A, Barancoková M, Harrington V, Volkovová K, Staruchová M, Horská A, Wsólová L, Kocan A, Petrík J, Machata M, Ratcliffe B, Kyrtopoulos S (2004) Genotoxic effects of asbestos in humans. Mutat Res Fund Mol Mech Mutagen 553:91–102

Frasca DR, Gehrig LE, Clarke MJ (2001) Cellular effects of transferrin coordinated to [Cl(NH₃)₅Ru]Cl₂ and cis-[Cl₂(NH₃)₄Ru]Cl. J Inorg Biochem 83:139–149

Galanski M, Arion VB, Jakupec MA, Keppler BK (2003) Recent developments in the field of tumorinhibiting metal complexes. Curr Pharm Des 9:2078–2089

Ge H, Kong X, Shi L, Hou L, Liu Z, Li P (2009) Gamma-linolenic acid induces apoptosis and lipid peroxidation in human chronic myelogenous leukemia K-562 cells. Cell Biol Int 33:402–410

Hartinger CG, Zorbas-Seifried S, Jakupec MA, Kynast B, Zorbas H, Keppler BK (2006) From bench to bedside - preclinical and early clinical development of the anticancer agent indazolium *trans*-[tetrachloro bis(1Hindazole)ruthenate (III)] (KP1019 or FFC144). J Inorg Biochem 100:891–904

Hotze ACG, Geer EPL, Caspers SE, Kooijman H, Haasnoot JG, Reedijk J (2004) Inorg Chem 43:4935–4943

Jakupec MA, Arion VB, Kapitza S, Reisner E, Eichinger A, Pongratz M, Graf von Keyserlingk N, Keppler BK (2005) KP1019 (FFC14A) from bench to bedside: preclinical and early clinical development. Int J Clin Pharmacol Ther 43:595–596

Kapitza S, Pongratz M, Jakupec MA, Heffeter P, Berger W, Lackinger L, Keppler BK, Marian B (2005) Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells. J Cancer Res Clin Oncol 131:101–110

Katsaros N, Anagnostopoulou A (2002) Rhodium and its compounds as potential agents in cancer treatment (critical reviews). Crit Rev Oncol Hematol 42:297–308

Kelland LR, Farrell NP (2000) Platinum-based drugs in cancer therapy, vol 89. Humana Press NJ, Totowa, pp 251–275

Kim R, Tanabe K, Uchida Y, Emi M, Inoue H, Toge T (2002) Current status of the molecular mechanisms of anticancer drug-induced apoptosis e the contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother Pharmacol 50:343–352

Kostova J (2006) Ruthenium complexes as anticancer agents. Curr Med Chem 13:1085–1107

Lebwohl D, Canetta R (1998) Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 34:1522–1534

Leung C-H, Zhong H-J, Yang H, Cheng Z, Chan DS-H, Ma VP-Y, Abagyan R, Wong C-Y, Ma D-L (2012) A metal-based inhibitor of tumor necrosis factor-a. Angew Chem 51:9010–9014

Liu YJ, Zeng CH, Liang ZH, Yao JH, Huang HL, Li ZZ, Wu FH (2010) Synthesis of ruthenium(II) complexes and characterization of their cytotoxicity *in vitro*, apoptosis, DNA-binding and antioxidant activity. Eur J Med Chem 45:3087–3095

Lung DM, Zhang HH, Ho KL, Hin DSC, Hang CL (2013) Bioactive luminescent transition-metal complexes for biomedical applications. Medicinal Inorganic Chemistry 52:7666–7682

Meggers E (2009) Targeting proteins with metal complexes. Chem Commun 7:1001–1010

Melchart M, Habtemarlam A, Novakova O, Moggach SA, Fabbiani FPA, Parsons S, Brabec V, Sadler PJ (2007) Inorg Chem 46:8950–8962

Menezes CSR, Costa LCGP, Avila VMR, Ferreira MJ, Vieira CU, Pavanin LA, Homsi-Brandeburgo MI, Hamaguchi A, Silveira-Lacerda EP (2007) Analysis in vivo of antitumor activity, cytotoxicity and interaction between plasmid DNA and the *cis*-dichlorotetraammineruthenium(III) chloride. Chem Biol Interact 167:116–124 Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival. J Immunol Methods 65:55–63

- Nunez G, Benedict MA, Hu Y, Inohara N (1998) Caspases: the proteases of the apoptotic pathway. Oncogene 17:3237–3245
- Panchal RG (1998) Novel therapeutic strategies to selectively kill cancer cells. Biochem Pharmacol 55:247–252
- Pereira FC, Vilanova-Costa CAST, Lima AP, Ribeiro ASBB, da Silva HD, Pavanin LA, Silveira-Lacerda EP (2009) Cytotoxic and genotoxic effects of *cis*-tetraammine (oxalato)ruthenium(III) dithionate on the root meristem cells of Allium cepa. Biol Trace Elem Res 128(3):258–268

Pluim D, Van Waardenburg RC, Beijnen JH, Schellens JH (2004) Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines. Cancer Chemother Pharmacol 54:71–78

Ribeiro ASBB, Da Silva CC, Pereira FC, Lima AP, Vilanova-Costa CAST, Aguiar SS, Pavanin LA, Da Cruz AD, Silveira-Lacerda EP (2009) Mutagenic and genotoxic effects of *cis*-(dichloro)tetraammineruthenium(III) chloride on human peripheral blood lymphocytes. Biol Trace Elem Res 130:249–261

Robert J, Jarry C (2003) Multidrug resistance reversal agents. J Med Chem 46:4805–4817 Ronconi L, Sadler PJ (2007) Using coordination chemistry to design new

medicines. Coord Chem Rev 251:1633-1648

Rosenberg B, Van Camp L, Krigas T (1965) Inhibition of cell division in *Escherichia coli* by electrolysis products from a platinum electrode. Nature 205:698–699

Sanna B, Debidda M, Pintus G, Tadolini B, Posadino AM, Bennardini F, Sava G, Ventura C (2002) The anti-metastatic agent imidazolium *trans*imidazoledimethylsulfoxide-tetrachlororuthenate induces endothelial cell apoptosis by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway. Arch Biochem Biophys 403:209–218

Sava G, Bergamo A (2000) Ruthenium-based compounds and tumour growth control (review). Int J Oncol 17:353–365

Sava G, Capozzi I, Clerici V, Gagliardi G, Alessio E, Mestroni G (1998) Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex. Clin Exp Metastasis 16:371–379

Schatzschneider U, Niesel J, Ott I, Gust R, Alborzinia H, Wölfl S (2008) Cellular uptake, cytotoxicity, and metabolic profiling of human cancer cells treated with ruthenium(II) polypyridyl complexes [Ru(bpy)2(N–N)]Cl2 with N–N¼bpy, phen, dpg, dppz, and dppn. Chem Med Chem 3:1104–1109

Sekihashi K, Yamamoto A, Matsumura Y, Ueno S, Watanabe-Akanuma M, Kassie F, Knasmüller S, Tsuda S, Sasaki YF (2002) Comparative investigation of multiple organs of mice and rats in the comet assay. Mutat Res Fund Mol Mech Mutagen 517:53–75

Silveira-Lacerda EP, Vilanova-Costa CAST, Hamaguchi A, Pavanin LA, Goulart LR, Homsi-Brandenburgo MI, dos Santos WB, Soares AM, Nomizo A (2009) The ruthenium complex *cis*-(Dichloro)tetraammineruthenium(III) chloride presents selective cytotoxicity against murine B cell lymphoma (A-20), murine ascitic sarcoma 180 (S-180), human breast adenocarcinoma (SK-BR-3), and human T cell leukemia (Jurkat) tumor cell lines. Biol Trace Elem Res 135:98–111

Štarha P, Trávnícek Z, Popa I (2009) Synthesis, characterization and in vitro cytotoxicity of the first palladium(II) oxalato complexes involving adenine-based ligands. J Inorg Biochem 103:978–988

Trzeciak AR, Kowalik J, Małecka-Panas E, Drzewoski J, Wojewodzka M, Iwanenko T, Błasiak J (2000) Genotoxicity of chromium in human gastric mucosa cells and peripheral blood lymphocytes evaluated by the single cell gel electrophoresis (comet assay). Med Sci Monit 6:24–29

Witte I, Plappert U, de Wall H, Hartmann A (2007) Genetic toxicity assessment: employing the best science for human safety evaluation part III: the comet assay as an alternative to *in vitro* clastogenicity tests for early drug candidate selection. Toxicol Sci 97:21–26

Yan YK, Melchart M, Habtemariam A, Sadler PJ (2005) Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes. Chem Commun 38:4764–4776

Yang X, Chen L, Liu Y, Yongguang Y, Chen T, Zheng W, Liu JA, Qing-Yu HE (2012) Ruthenium methylimidazole complexes induced apoptosis in lung cancer A549 cells through intrinsic mitochondrial pathway. Biochimie 94:345–353

Zorzet S, Sorce A, Casarsa C, Cocchietto M, Sava G (2001) Pharmacological effects of the ruthenium complex NAMI-A given orally to CBA mice with MCa mammary carcinoma. Met Based Drugs 8:1–7

doi:10.1186/2193-1801-3-301

Cite this article as: Pereira *et al.*: Cytotoxic effects of the compound *cis*tetraammine(oxalato)ruthenium(III) dithionate on K-562 human chronic myelogenous leukemia cells. *SpringerPlus* 2014 3:301.